Patents Assigned to Celtaxsys, Inc.
-
Patent number: 10501455Abstract: The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.Type: GrantFiled: December 13, 2017Date of Patent: December 10, 2019Assignee: Celtaxsys, Inc.Inventor: William Guilford
-
Patent number: 10399986Abstract: The present invention is directed to compounds encompassed by the Formula (I): pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.Type: GrantFiled: September 14, 2017Date of Patent: September 3, 2019Assignee: Celtaxsys, Inc.Inventor: William Guilford
-
Patent number: 10385007Abstract: This present disclosure is directed to compounds of formula (I): where r, q, R1a, R1b, R1c, R1d, R1e, R2, R3, R4a, R5a, R5b, R6a, R6b, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.Type: GrantFiled: December 11, 2017Date of Patent: August 20, 2019Assignee: Celtaxsys, Inc.Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
-
Patent number: 10350197Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.Type: GrantFiled: November 2, 2017Date of Patent: July 16, 2019Assignee: Celtaxsys, Inc.Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
-
Patent number: 10202334Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R1b, R1c, R1d, R1e, R3, R4a, R4b, R4c, R4d, R6, R7, and R8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.Type: GrantFiled: December 11, 2017Date of Patent: February 12, 2019Assignee: Celtaxsys, Inc.Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
-
Patent number: 10202362Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R3, Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.Type: GrantFiled: December 11, 2017Date of Patent: February 12, 2019Assignee: Celtaxsys, Inc.Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
-
Patent number: 9856249Abstract: The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.Type: GrantFiled: September 10, 2015Date of Patent: January 2, 2018Assignee: Celtaxsys, Inc.Inventor: William Guilford
-
Patent number: 9822106Abstract: The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.Type: GrantFiled: September 10, 2015Date of Patent: November 21, 2017Assignee: CELTAXSYS, INC.Inventors: William Guilford, David Davey
-
Patent number: 9820974Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.Type: GrantFiled: September 10, 2015Date of Patent: November 21, 2017Assignee: Celtaxsys, Inc.Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
-
Patent number: 9777006Abstract: The present invention is directed to compounds encompassed by the Formula (I): pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.Type: GrantFiled: September 10, 2015Date of Patent: October 3, 2017Assignee: Celtaxsys, Inc.Inventor: William Guilford
-
Patent number: 9617330Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.Type: GrantFiled: February 2, 2010Date of Patent: April 11, 2017Assignee: Celtaxsys, Inc.Inventors: Hyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner
-
Patent number: 9315509Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: GrantFiled: June 24, 2014Date of Patent: April 19, 2016Assignee: Celtaxsys, Inc.Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Publication number: 20140294862Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.Type: ApplicationFiled: March 20, 2014Publication date: October 2, 2014Applicant: Celtaxsys, Inc.Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
-
Patent number: 8715654Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.Type: GrantFiled: October 2, 2009Date of Patent: May 6, 2014Assignee: Celtaxsys, Inc.Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
-
Publication number: 20140031321Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: ApplicationFiled: January 14, 2013Publication date: January 30, 2014Applicant: CELTAXSYS, INC.Inventor: Erica Brook Goodhew
-
Patent number: 8569303Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: GrantFiled: April 30, 2010Date of Patent: October 29, 2013Assignee: Celtaxsys, Inc.Inventors: Damian O Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J Kochanny, Amy Liang, David Light, John Parkinson, David Vogel, Guo Ping Wei, Bin Ye
-
Patent number: 8377914Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, Synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: GrantFiled: October 9, 2009Date of Patent: February 19, 2013Assignee: Celtaxsys, Inc.Inventor: Erica Brook Goodhew